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Abstract
Background: Several studies have shown that the predominant genotype of Chinese Japanese encephalitis virus (JEV) is
evolving from genotype 3 to genotype 1. However, in recent years, almost all genotype 1 isolates were from mosquitoes,
and genotype 1 has been less associated with human disease than genotype 3. This study reports the isolation of human
genotype 1 JEV and its genetic characteristics to provide additional insights into human JE pathogens that are currently
circulating in China.
Methods and Results: In 2009, 31 cerebrospinal fluid samples were collected from patients living in Yunnan and Shanxi
provinces and were used to inoculate Aedes albopictus C6/36 cells for virus isolation. The JEV strains were identified using
immunofluorescent assays and the reverse transcription-polymerase chain reaction. Phylogenetic analyses based on the
partial capsid/pre-membrane and full envelope (E) sequences were performed using Clustalx 1.8 software. Three JEV isolates
were obtained from a 4-year-old girl and a 2-year-old boy living in Yunnan and an 82-year-old woman in Shanxi. The boy
had been immunized with one dose of JE live attenuated vaccine. New isolates were grouped into genotype 1. Amino acid
sequence for the viral E protein indicated 95% to 100% identity with each other and with other JEV strains. When compared
with a consensus sequence of E protein, two amino acid substitutions were found: Ser
E-123-Asn in the two Yunnan isolates
and Lys
E-166-Arg in the Shanxi isolate.
Conclusions: Our findings indicate that the genotype 1 of JEV is causing human infections in China. Our observation of a
previously vaccinated boy developing JE from genotype 1 virus infection also calls for more detailed studies, both in vitro
and in vivo neutralization tests as well as active surveillance, to examine the possibility of a lack of complete protection
conferred by the live attenuated JE vaccine against genotype 1 virus.
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Introduction
Japanese encephalitis (JE) is prevalent in eastern and southern
Asia.Anestimated3billionpersonsliveinareaswhere JE is endemic
and the annual incidence of the disease in these areas is 30,000–
50,000 cases [1,2]. Approximately 25%–30% of cases are fatal, and
50% result in irreversible neuropsychiatric sequelae. The disease
primarily affects children and adolescents. In China, JE is the most
important viral encephalitis and is one of four currently circulating
arbovirus diseases [3]. Epidemic JE activity has been detected in the
last 60 years in most provinces of mainland China, except for
Xinjiang Uygur Autonomous, Tibet and Qinghai Province.
Although nationwide immunization has dramatically reduced the
disease incidence, there are still 8,000–10,000 cases reported
annually, contributing significantly to the global disease burden [4].
JE virus (JEV), a member of the genus Flavivirus of the family
Flaviviridae, is maintained in nature through a transmission cycle
involving the Culex species mosquitoes, pigs, bats, and water birds
[5]. The viral genome is a positive-sense, single-stranded RNA
that contains a single open reading frame encoding three
structural proteins designated capsid (C), pre-membrane/mem-
brane (prM/M) and envelope (E), and seven non-structural
proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [6].
Partial sequence analysis of the C/prM gene indicates that JEV
strains can be classified into four genotypes [7,8].
In China, genotype 3 JEV was the predominant genotype
before 2001, but since then, genotype 1 isolates have been
frequently detected [9]. Moreover, an outbreak of JE occurred in
2006 in the Chinese province of Shanxi; the outbreak consisted of
66 cases with a 28.8% fatality rate, and both genotypes 1 and 3
were detected in the patients [10]. These observations imply that
the predominant genotype of Chinese JEV is changing from
genotype 3 to genotype 1 or that the co-circulation of the two
genotypes is becoming common. However, most of the genotype 1
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furthermore, this genotype been less associated with human
disease than genotype 3 [11,12]. The general lack of knowledge
regarding the prevalence and severity of genotype 1 JEV led us to
investigate the predominant JEV genotype within a group of JE
patients in China. In the present study, we report the isolation of
genotype 1 JEV in humans and the genetic characteristics of the E
protein of this genotype.
Materials and Methods
Ethics statement
The study was performed after consultation with the patients or
their guardians and after the receipt of written consent. The study-
related information was used anonymously. The Institutional
Review Board of the Beijing Institute of Microbiology and
Epidemiology approved the research involving human materials.
The animal experiments were approved by the Animal Subjects
Research Review Board of the Beijing Institute of Microbiology
and Epidemiology and were conducted according to the
institution’s guidelines for animal husbandry.
Sample collection
From June to August 2009, a total of 78 patients who had a
clinical diagnosis of viral encephalitis were hospitalized: 19 from
Luxi City and 30 from Banna in Yunnan Province; 5 from Linyi
County and 24 from Taiyuan City in Shanxi Province.
Cerebrospinal fluid (CSF) samples were collected from all 78
patients. Thirty-five cases were determined to be JE with positive
findings of IgM antibodies in the CSF samples. The 31 CSF
samples collected within five days of illness onset were selected
for virus isolation. Yunnan Province, located in southern China,
has a tropical to subtropical climate and a high JE incidence
(.1/100,000 people). Shanxi Province, located in middle China,
has a JE incidence rate of 0.1–0.5/100,000 people [13]. Linyi
County was a main epidemic area in the 2006 JE outbreak
mentioned above. All samples were stored in liquid nitrogen until
tested.
Viral isolation and identification
The CSF specimens were diluted at a 1:5 ratio with RPMI-
1640 medium containing 2% fetal calf serum and cultured with
Aedes albopictus C6/36 cells for 7–10 days. Cultures were
examined daily for evidence of a virally-induced cytopathic effect
(CPE). Infected-cells that showed CPE were harvested and
identified as JEV-positive by an immunofluorescent assay (IFA)
using JEV-polyclonal antisera. The culture supernatant was
filtered with a 0.22-mm filter and was then used to inoculate
suckling mice intracebrally for an evaluation of the pathogenicity
of the isolated virus. Cultures without CPE were blind-passaged 3
times.
Total RNA was extracted from the infected C6/36 cell culture
using Trizol and reverse-transcribed with random hexamers to
obtain first-strand cDNA. For primary molecular identification,
PCR was performed with a pair of JEV-specific primers in the
NS1 region: 59-GTGCCATTGACATCACAAG-39 and 59-TG-
TCTCAGGTCCATCTACG-39. In JEV-positive samples, partial
C/prM (675 bp) and the full E genes of JEV were amplified as
described by Wang et al. [9]. PCR products were directly
sequenced using an automated DNA sequencer (ABI PRISM 373,
Perkin-Elmer, USA). The DNA was sequenced using both forward
and reverse primers to verify the sequences. The sequences were
subjected to a BLAST search.
Phylogenetic analysis
A total of 50 JEV sequences were used for phylogenetic
analyses, including 39 representative Chinese sequences. Multiple
sequence alignments were carried out using Clustalx 1.8 software
[14]. Phylogenetic trees were generated using the Bayesian
Metropolis-Hastings Markov Chain Monte Carlo (MCMC) tree-
sampling methods implemented by Mr. Bayes 3.1 software. We
used the GTR model as the evolutionary model with gamma-
distributed rate variation across sites and a proportion of
invariable sites [15]. The run was stopped when the standard
deviation of split frequencies was below 0.01. A West Nile virus
(WNV-NY99) sequence was used as an out-group control.
Results
Case summaries
The basic characteristics of the patients are summarized in
Table 1. The patients from Luxi City and Taiyuan City were
almost all children or adolescents, with an average age of 8–9
years. In contrast, the patients from Linyi County were all adults;
of the five cases, three were .60 years old, with an average age of
55 years.
Viral isolates were obtained from a 4-year-old girl, a 2-year-old
boy and an 82-year-old woman, designated as LX10P-09, LX29P-
09 and LY5P-09, respectively. The positive isolation rate was
approximately 10%. Both the 4-year old girl and 2-year old boy
lived in Luxi City, Yunnan Province. The girl visited a local
hospital on July 7 with symptoms of fever, headache, vomiting,
convulsion and drowsiness. Neck stiffness was also noticed. The
boy visited the same hospital on June 30 with symptoms of fever,
and vomiting. He received one dose of live-attenuated JE
vaccination 15 months prior to presentation. The woman patient,
residing in Linyi County, was hospitalized on August 13 for fever,
vomiting, drowsiness and convulsion. According to the case
definition by the Ministry of Health of the People’s Republic of
China, the girl, woman and boy patients were recognized as
having clinically severe, very severe and mild JE, respectively.
Their acute-phase CSF samples were collected at day 1–2 after the
onset of illness. The JEV-specific immunoglobulin M (IgM)
antibodies from the CSF, measured by IgM antibody-capture
enzyme-linked immunosorbent assay (MAC-ELISA), were positive
in the girl patient but negative in two other cases (Table 2).
Viral isolation
The virus isolates induced CPE in first-passage C6/36 cells on
day 5–6 after inoculation. Cell shrinking, shedding, fusion or
cytolysis characterized the CPE. Cells infected by the viral isolates
all reacted with JEV-polyclonal antisera in IFA. Suckling mice that
were inoculated intracerebrally with the isolates all became ill and
died within 48–96 h. The three viral isolates studied were positive
for JEV RNA; the JEV-positive samples were identified by RT-
Table 1. Basic characteristics of the patients participating in
this study.
Area Number Male/Female
Average age
(range) (yrs)
Luxi City, Yunnan 20 16/4 9 (2–23)
Linyi County, Shanxi 5 3/2 55 (29–82)
Taiyuan City, Shanxi 6 3/3 8 (4–10)
doi:10.1371/journal.pone.0016418.t001
Genotype 1 JEV in Humans
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and were matched to JEV using a BLAST search. The sequences
of partial C/prM and full E genes were deposited into
the GenBank database with accession numbers GU371870,
HM204528 (LX10P-09), GU371871, HM204529 (LX29P-09)
and GU371872, HM204530 (LY5P-09).
Genetic characteristics of the isolates
A 240 bp fragment of the 675 bp C/prM gene was utilized for
multiple sequence alignments and phylogenetic analyses. This
region was used to determine the genotype of JEV. Except for
Indonesia JKT6468 which was recognized as genotype 4, 49
sequences were grouped into two distinct phylogenetic groups with
high bootstrap support (Fig. 1). The Australian FU recognized as
JEV genotype 2 was classified into its own clade. Another cluster in
the same major group consisted of 27 closely related sequences
and branched into many minor clades. The three isolates from this
study grouped into the same clade with 7 other strains isolated
within the past five years including one Japanese and 6 Chinese
sequences: SX06CSF-11, SX06M-5 and SX06M-18 from Shanxi,
HN04-11 from Henan, SC04-15 from Sichuan, SH05-24 from
Shanghai City, and JEV/sw/Mie/40/2004 from Japan. The new
isolates were classified as JEV genotype 1.
A phylogenetic tree according to the full E sequence revealed a
similar trend with the tree based on the C/prM region (Fig. 2). The
three new isolates were genetically related to each other and had
high similarity (99.6%–100%) with respect to the deduced amino
acid sequence of E protein. When compared to other JEV strains
used in this study, they had 81.4%–98.9% identity at the nucleotide
level and 95.2%–100% identity at the amino acid level. There was
97.0% homology with the Chinese vaccine strain SA14-14-2
(attenuated SA14). Table 3 summarizes the amino acid differences
in the E protein sequence among the new isolates and SA14-14-2
strain. There were 16 substitutions in the 500 amino acid residues of
E protein. When compared with the consensus sequence from 46 E
proteins, two amino acid residues were different: Ser
E-123RAsn in
the two Yunnan isolates and Lys
E-166RArg in the Shanxi isolate.
Discussion
In recent years, JEV genotype 1 has been frequently isolated at
different geographical areas in mainland China including Liaoning
(2002), Sichuan (2004), Henan (2004), Shandong (2009), Guizhou
(2010) and Shanghai (2001, 2003, 2005, 2007) [9,12,16,17].
However, these isolates were primarily from mosquito pools or
porcine samples. Since the early-1990s, human JEV isolation was
neglected in China, and the isolation of genotype 1 JEV in human
was rarely reported [12]. Using RT-PCR, Wang et al. [10]
detected nucleotide segments of JEV from human CSF samples
acquired in 2006, and four of six cases were classified as genotype
1. Further evidence of genotype 1 JEV circulation was found with
the analysis of meningitis patients in Japan [11]. In the present
study, three JEV isolates in patients from Yunnan and Shanxi
were classified into genotype 1. It would be interesting to
determine whether genotype 1 has become the predominant
genotype among human JE cases in China. To confirm this
finding, additional human isolates will be necessary.
Yunnan Province is a region with a high incidence of JE [13].
Controlling the JE incidence in Yunnan is crucial to decreasing the
disease burden in China. A limited survey showed that more than
10% of mosquito pools were positive for JEV in 2007 and 2008
(our unpublished data), indicating that JEV is still prevalent in
Yunnan. We obtained JEV strains from two ill patients in this
area: a young boy and girl. Unexpectedly, the boy patient had
been immunized with one dose of JE live attenuated vaccine,
which is prepared based on genotype 3 of JEV and used
commonly for human vaccination in China [18]. It is unknown
whether the boy’s infection results from a lack of immune response
to or protective immunity against circulating JEV. To answer this
question, neutralization tests on acute and convalescent serum
samples should be conducted. Unfortunately, we could not obtain
serum samples from the patient. The boy patient was a clinically
mild case without reduced level of consciousness, neck stiffness or
convulsion. Interestingly, we found that another patient, a 4-year-
old boy, had also previously received one dose of a JE vaccine, and
he was also confirmed as having JE and positive JEV-IgM in his
CSF, but revealed mild clinical manifestations. It is tempting to
speculate that JE vaccination might alleviate symptoms of the
disease, even though it may not prevent infection by JEV.
Although Shanxi Province was not at high risk for a JE
epidemic, an outbreak of viral encephalitis occurred in Yuncheng,
Shanxi Province, in 2006. Generally, JE affects children, but
during the 2006 Shanxi outbreak, a higher adult incidence was
observed; in fact, approximately 95% of the disease-related deaths
occurred in patients over 50 years old [10]. We identified five
patients with viral encephalitis in Linyi County, Yuncheng in
2009, and all patients were adults with an average age of 55 years.
This observation suggested that adults, especially the elderly, in
this region are at higher risk of JE; it is reasonable, therefore, that
public health officers should recommend JE vaccination to this
population. Overall, there is less information about JEV strains
from Shanxi Province. We isolated JEV from an 82-year-old
patient, and to our knowledge, it is the first isolate from an elderly
patient. Analysis of a larger number of isolates along with that
reported in this study would be needed to determine the
transmission pattern of JE in various Shanxi Province.
The E protein of flaviviruses, including JEV, plays an important
role inimmunogenicity,tissue tropism,cell fusion and infection, and
virus maturation [19]. Several studies have suggested that some
amino acid substitutions in the E protein may be related to the
virulence of JEV. Through a comparison of the amino acid
sequences between wild-type SA14 and its attenuated strains, Ni et
al. [20] found that mutations in E138 (GluRLys), E176 (IleRVal),
E315 (AlaRVal) and E439 (LysRArg) may contribute to the
Table 2. Summarized data of the patients from whom the viruses were isolated.
Gender
Age
(yrs) Residence
JE
vaccination Clinical type
JEV-IgM
in CSF Isolate
Patient 1 female 4 Luxi City unknown severe positive LX10P-09
Patient 2 male 2 Luxi City yes mild negative LX29P-09
Patient 3 female 82 Linyi County no very severe negative LY5P-09
doi:10.1371/journal.pone.0016418.t002
Genotype 1 JEV in Humans
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isolates were identical to the wild SA14 straininthese sites (Table 3).
Recently, Tajima et al. [21] demonstrated that a single mutation in
E123 (Ser to Arg) resulted in a significantly increased viral growth
rateinmouseneuroblastoma cells;ThetwoYunnanisolatesshowed
a mutation in E123 (Ser to Asn), but the biological significance of
this mutation is unknown.
Previous reports showed that the antigenic epitopes of JEV are
located within certain regions of the E protein; for example,
residues 331 and 332 were shown to be part of a neutralizing
epitope, and residues 60–68 are recognized by cytotoxic T
lymphocytes [22–24]. The new isolates did not have any changes
compared to the JE vaccine strain SA14-14-2 in these regions.
However, considering the case of the boy who has been vaccinated
Figure 1. Phylogenetic tree based on the C/prM gene of the representative JEV strains. The details of the strains, except SX06CSF-3,
SX06CSF-11 (China, Shanxi, human CSF, 2006), and SX06M-5, SX06M-18 (China, Shanxi, mosquito, 2006), are presented in Figure 2. WNV NY99
(NC_009942) was used as an out-group. JEV Genotypes 1–4 are expressed as G1–G4, respectively. An asterisk is used to denote the three isolates used
in this study.
doi:10.1371/journal.pone.0016418.g001
Genotype 1 JEV in Humans
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JEV Genotypes 1–4 are expressed as G1–G4, respectively. An asterisk is used to denote the three isolates used in this study.
doi:10.1371/journal.pone.0016418.g002
Genotype 1 JEV in Humans
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16418with the live attenuated JE vaccine but developed mild JE,
protective immunity to JEV may be also related with the mutation
in other viral proteins besides E protein. Several studies have
demonstrated that the NS1 protein induced protective immune
responses against lethal JEV challenge. When immunized with the
plasmid expressing NS1, 90% of the mice survived after a lethal
JEV challenge, whereas when injected with the plasmid expressing
prM plus E, 70% of the immunized mice survived after a lethal
challenge [25]. Pigs vaccinated with recombinant pseudorabies
virus expressing NS1 protein of JEV SA14-14-2 strain could
develop a good humoral and cellular immune response against
JEV [26]. A recent report indicated a high immunogenicity and
significant protection of E. coli synthesized NS1 protein to JEV in
the mice [27]. In addition, the mutations in other E regions of new
isolated strains, which were not reported to be associated with
protective immunity, should be concerned.
Our findings indicate that the genotype 1 of JEV is causing
human infections in China. Our observation of a previously
vaccinated boy developing JE from genotype 1 virus infection also
calls for more detailed studies, both in vitro and in vivo
neutralization tests as well as active surveillance, to examine the
possibility of a lack of complete protection conferred by the live
attenuated JE vaccine against genotype 1 virus.
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